title: Effects of simvastatin and rosuvastatin on RAS protein, matrix metalloproteinases and NF-κB in lung cancer and in normal pulmonary tissues.
abstract: OBJECTIVE
  In this study, we have evaluated effects of 24-hour treatments with simvastatin or rosuvastatin on RAS protein, NF-κB and MMP expression in LC tissues obtained from 12 patients undergoing thoracic surgery.
  
  
  METHODS
  Normal and lung tumour tissues obtained from each sample were exposed to simvastatin (2.5-30 μm) or rosuvastatin (1.25-30 μm) and western blot analysis was then performed.
  
  
  RESULTS
  We documented increased expression of proteins, MMP-2, MMP-9 and NF-κB-p65 in LC tissues, with respect to normal tissues (P < 0.01). In the malignant tissues, simvastatin and rosuvastatin significantly (P < 0.01) and dose-dependently reduced RAS protein, MMP-2/9 and NF-κB-p65 expression.
  
  
  CONCLUSIONS
  In conclusion, our results suggest that simvastatin and rosuvastatin could play a role in LC treatment by modulation of RAS protein, MMP-2/9 and NF-κB-p65.
authors.affiliation: Department of Health Science, School of Medicine, University of Catanzaro, Catanzaro, Italy.
authors.forename: D
authors.initials: D
authors.lastname: Falcone
authors.forename: L
authors.initials: L
authors.lastname: Gallelli
authors.forename: A
authors.initials: A
authors.lastname: Di Virgilio
authors.forename: L
authors.initials: L
authors.lastname: Tucci
authors.forename: M
authors.initials: M
authors.lastname: Scaramuzzino
authors.forename: R
authors.initials: R
authors.lastname: Terracciano
authors.forename: G
authors.initials: G
authors.lastname: Pelaia
authors.forename: R
authors.initials: R
authors.lastname: Savino
mesh_terms: D000230:Adenocarcinoma / Q000201:enzymology / Q000378:metabolism / Q000473:pathology*; D000077192:Adenocarcinoma of Lung; D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology; D014408:Biomarkers, Tumor / Q000378:metabolism; D015153:Blotting, Western; D016022:Case-Control Studies; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D005260:Female; D005464:Fluorobenzenes / Q000494:pharmacology*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008168:Lung / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008175:Lung Neoplasms / Q000201:enzymology / Q000378:metabolism / Q000473:pathology*; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000235:genetics / Q000378:metabolism*; D020780:Matrix Metalloproteinase 9 / Q000235:genetics / Q000378:metabolism*; D008875:Middle Aged; D011743:Pyrimidines / Q000494:pharmacology*; D000068718:Rosuvastatin Calcium; D019821:Simvastatin / Q000494:pharmacology*; D012907:Smoking / Q000009:adverse effects; D013449:Sulfonamides / Q000494:pharmacology*; D051996:Transcription Factor RelA / Q000235:genetics / Q000378:metabolism*; D014407:Tumor Cells, Cultured; D018631:ras Proteins / Q000235:genetics / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D005464:Fluorobenzenes; D011743:Pyrimidines; C498143:RELA protein, human; D013449:Sulfonamides; D051996:Transcription Factor RelA; D000068718:Rosuvastatin Calcium; D019821:Simvastatin; C522361:MMP2 protein, human; D020778:Matrix Metalloproteinase 2; C579270:MMP9 protein, human; D020780:Matrix Metalloproteinase 9; D018631:ras Proteins